C. Kedor

发表

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

E. Feist, H. Schulze-Koops, J. Listing, 2020, Annals of the Rheumatic Diseases.

Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis

Andreas Radbruch, A. Thiel, U. Syrbe, 2011, The Journal of Rheumatology.

Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany: a first analysis of a prospective observational study

H. Volk, C. Scheibenbogen, J. Bellmann-Strobl, 2021, medRxiv.

Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis

D. Huscher, G. Burmester, G. Burmester, 2022, Frontiers in Immunology.

Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity

F. Paulus, F. Paul, Myungjin Kim, 2022, Frontiers in Immunology.

A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity

H. Volk, C. Scheibenbogen, J. Bellmann-Strobl, 2022, Nature Communications.

Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS Differentially Affects Endothelial Cell Function In Vitro

C. Scheibenbogen, M. Seifert, C. Kedor, 2022, Cells.

Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

C. Meisner, D. Kofler, E. Feist, 2022, Journal of clinical medicine.

Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS)

F. Paul, C. Scheibenbogen, J. Bellmann-Strobl, 2022, Journal of Translational Medicine.

Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS

C. Scheibenbogen, W. Doehner, N. Scherbakov, 2021, Journal of translational medicine.

Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.

M. Boubaya, F. Mendoza, J. D. de Vries-Bouwstra, 2022, The Lancet. Rheumatology.

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren’s syndrome

G. Burmester, E. Feist, J. Callhoff, 2016, Clinical Rheumatology.

Author Correction: A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity

H. Volk, C. Scheibenbogen, J. Bellmann-Strobl, 2022, Nature Communications.

Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

C. Scheibenbogen, G. Riemekasten, T. Lange, 2021, Journal of clinical medicine.

Post-COVID syndrome is associated with capillary alterations, macrophage infiltration and distinct transcriptomic signatures in skeletal muscles

F. Heppner, M. Landthaler, C. Scheibenbogen, 2023, medRxiv.

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review

E. Feist, C. Kedor, D. Baeumer, 2021, Therapeutic advances in musculoskeletal disease.

Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

C. Scheibenbogen, N. Sepúlveda, C. Kedor, 2021, Frontiers in Immunology.

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

C. Meisel, S. Gläser, H. Volk, 2022, Frontiers in Immunology.

Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS)

F. Paul, C. Scheibenbogen, J. Bellmann-Strobl, 2022, Journal of translational medicine.

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab

D. Foell, E. Feist, G. Burmester, 2021, Journal of clinical medicine.

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis

G. Burmester, E. Feist, C. Kedor, 2016, BMC Musculoskeletal Disorders.

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

G. Burmester, T. Häupl, E. Feist, 2020, RMD open.

Symptom persistence and biomarkers in post-COVID-19/chronic fatigue syndrome - results from a prospective observational cohort

C. Scheibenbogen, J. Bellmann-Strobl, F. Konietschke, 2023, medRxiv.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

F. Buttgereit, R. Rau, S. Wassenberg, 2021, RMD Open.

Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova

E. Feist, C. Kedor, J. Zernicke, 2020, Annals of the Rheumatic Diseases.

Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al

E. Feist, J. Listing, C. Kedor, 2020, Annals of the Rheumatic Diseases.

SAT0108 RESPONSE TO ABATACEPT IS ASSOCIATED WITH THE INHIBITION OF PROTEASOME Β1I EXPRESSION IN T CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS

E. Feist, G. Burmester, C. Kedor, 2020, Annals of the Rheumatic Diseases.

THU0399 Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren's Syndrome (PSS) with Articular Involvement – Results of a Pilot Study

J. Callhoff, C. Kedor, J. Zernicke, 2015 .

THU0561 CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL‘S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER)

E. Feist, H. Schulze-Koops, J. Listing, 2019, Poster Presentations.

Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study

E. Feist, H. Schulze-Koops, J. Listing, 2019, SSRN Electronic Journal.